Purple Biotech (NASDAQ:PPBT) Shares Climb 5.1% – Here’s What Happened

Shares of Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) traded up 5.1% on Monday. The stock traded as high as $1.23 and last traded at $1.23. Approximately 18,933 shares traded hands during trading, a decline of 13% from the average session volume of 21,716 shares. The stock had previously closed at $1.17.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of Purple Biotech from a “sell (e+)” rating to a “sell (e)” rating in a report on Thursday, October 29th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Purple Biotech currently has an average rating of “Hold” and an average target price of $30.00.

Purple Biotech Trading Up 3.8%

The company’s fifty day moving average is $1.44 and its 200 day moving average is $2.96. The company has a market capitalization of $1.13 million, a P/E ratio of -0.05 and a beta of 0.77.

Purple Biotech (NASDAQ:PPBT) last released its quarterly earnings data on Friday, August 7th. The company reported $1.07 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.98) by $2.05. Equities research analysts predict that Purple Biotech Ltd. Sponsored ADR will post -5.73 EPS for the current year.

Purple Biotech Company Profile

Purple Biotech Ltd. (NASDAQ:PPBT) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research programs are designed to address mechanisms that contribute to tumor growth, immune evasion and resistance to existing treatments.

Purple Biotech’s pipeline has included CM24, a humanized monoclonal antibody targeting CEACAM1, an immune checkpoint involved in tumor-immune interactions. The company has evaluated CM24 in combination with other cancer therapies, including immune checkpoint inhibitors, for advanced solid tumors such as metastatic pancreatic cancer.

The company has also developed NT219, a small-molecule therapy designed to inhibit IRS1 and IRS2 signaling pathways associated with cancer-cell survival and treatment resistance.